MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Intravitreal Therapy

  • Home
  • Intravitreal Therapy
Two-Year Outcomes of Intravitreal Pegcetacoplan in Managing Geographic Atrophy: Real-World Clinical Experience
Posted innews Ophthalmology

Two-Year Outcomes of Intravitreal Pegcetacoplan in Managing Geographic Atrophy: Real-World Clinical Experience

Posted by By MedXY 09/17/2026
Intravitreal pegcetacoplan significantly slowed geographic atrophy progression by 41% over two years, maintaining efficacy in clinical practice for AMD patients, with stable visual acuity decline and manageable safety.
Read More
  • Saroglitazar in Primary Biliary Cholangitis: Insights from a Phase 2b/3 Adaptive Randomized Trial
  • eHealth-Guided Exercise Enhances Peak Oxygen Uptake and Quality of Life Post-COVID-19: A Randomized Controlled Trial
  • Five-Year Outcomes of Arthroscopic Bankart Repair in Young Athletes With Minimal Glenoid Bone Loss: Recurrence, Return to Sport, and Risk Factors
  • Age-Related Differences Influence Outcomes of Long-Term Multimodal Stroke Intervention: Insights from the LAST-long Trial
  • Linking Oral Health to Liver Cancer Risk: Insights from a Nationwide Swedish Cohort Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top